Treatment of Apoe-/- mice with the SOAT2 selective inhibitor pyripyropene A caused reductions in cholesterol absorption, plasma VLDLc and LDLc concentration, cholesteryl oleate content of apoB-containing lipoproteins, and atherosclerosis progression [19]. The gene discussed is APOE; the disease is atherosclerosis.